Quantifying Her2 protein for optimal cancer therapy
AssigneesExpression Pathology, Inc., Department of Internal Medicine and Cancer Research, Seoul National University Hospital
InventorsYung-Jue Bang, Todd Hembrough, Eunkyung An, Do-Youn Oh
Life of this patent
Estimating the term…
Abstract
Improved methods of treatment are provided for patients suffering from cancer. The methods identify whether a tumor will be responsive to treatment with a therapeutic regime that includes anti-Her2 therapeutic agents. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in tumor cells collected from tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein.
Claims16
A method of treating a patient suffering from gastric cancer comprising:
- (a) quantifying the level of a specified Her2 fragment peptide in a protein digest prepared from a tumor sample obtained from the patient and calculating the level of the Her2 peptide in said sample by selected reaction monitoring using mass spectrometry;
- (b) comparing the level of said Her2 fragment peptide to a reference level, wherein said reference level is about 1825 amol/μg+/−250 amol/μg, and
- (c) treating the patient with a therapeutic regimen comprising standard chemotherapy and an effective amount of an anti-Her2 therapeutic agent when the level of the Her2 fragment peptide is higher than said reference level or
- (d) treating the patient with a therapeutic standard chemotherapy regimen that does not comprise an effective amount of an anti-Her2 therapeutic agent when the level of the Her2 fragment peptide is below said reference level.
Dependencies are inferred from the claim text.